Analysts Anticipate R1 RCM Inc. (NASDAQ:RCM) to Announce $0.13 Earnings Per Share

Wall Street brokerages predict that R1 RCM Inc. (NASDAQ:RCMGet Rating) will announce earnings of $0.13 per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for R1 RCM’s earnings, with estimates ranging from $0.09 to $0.16. R1 RCM reported earnings per share of $0.06 during the same quarter last year, which would suggest a positive year over year growth rate of 116.7%. The company is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that R1 RCM will report full year earnings of $0.47 per share for the current fiscal year, with EPS estimates ranging from $0.39 to $0.57. For the next financial year, analysts forecast that the firm will post earnings of $0.64 per share, with EPS estimates ranging from $0.53 to $0.73. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow R1 RCM.

R1 RCM (NASDAQ:RCMGet Rating) last posted its quarterly earnings data on Monday, May 9th. The healthcare provider reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The company had revenue of $385.70 million for the quarter, compared to analysts’ expectations of $384.18 million. R1 RCM had a return on equity of 29.44% and a net margin of 6.64%. The business’s revenue for the quarter was up 12.6% on a year-over-year basis. During the same period in the previous year, the business posted ($2.37) EPS.

RCM has been the subject of several recent research reports. Robert W. Baird raised their price target on shares of R1 RCM from $29.00 to $32.00 in a research report on Thursday, March 3rd. Zacks Investment Research cut shares of R1 RCM from a “buy” rating to a “hold” rating in a research report on Friday, May 13th. TheStreet raised shares of R1 RCM from a “d” rating to a “c” rating in a research report on Monday, May 9th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of R1 RCM from $30.00 to $28.00 in a research report on Tuesday, May 10th. Finally, Guggenheim initiated coverage on shares of R1 RCM in a research report on Wednesday, April 13th. They issued a “neutral” rating for the company. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $29.25.

Hedge funds and other institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC increased its stake in R1 RCM by 49.5% in the fourth quarter. ProShare Advisors LLC now owns 41,331 shares of the healthcare provider’s stock valued at $1,054,000 after purchasing an additional 13,686 shares during the period. Credit Suisse AG increased its stake in R1 RCM by 10.3% in the third quarter. Credit Suisse AG now owns 134,395 shares of the healthcare provider’s stock valued at $2,958,000 after purchasing an additional 12,551 shares during the period. Sunriver Management LLC increased its stake in R1 RCM by 58.7% in the third quarter. Sunriver Management LLC now owns 2,319,322 shares of the healthcare provider’s stock valued at $51,048,000 after purchasing an additional 857,490 shares during the period. Renaissance Technologies LLC increased its stake in R1 RCM by 7.9% in the third quarter. Renaissance Technologies LLC now owns 338,530 shares of the healthcare provider’s stock valued at $7,451,000 after purchasing an additional 24,732 shares during the period. Finally, Neuberger Berman Group LLC increased its stake in R1 RCM by 2.1% in the third quarter. Neuberger Berman Group LLC now owns 412,189 shares of the healthcare provider’s stock valued at $8,930,000 after purchasing an additional 8,481 shares during the period. Institutional investors own 41.97% of the company’s stock.

RCM stock traded up $0.05 during midday trading on Thursday, hitting $21.73. The company’s stock had a trading volume of 944,888 shares, compared to its average volume of 1,312,921. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 2.06. R1 RCM has a 52-week low of $18.71 and a 52-week high of $27.86. The firm has a market capitalization of $6.08 billion, a P/E ratio of 70.48, a PEG ratio of 2.55 and a beta of 0.86. The firm has a 50-day simple moving average of $24.56 and a 200-day simple moving average of $24.50.

R1 RCM Company Profile (Get Rating)

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.

Featured Stories

Get a free copy of the Zacks research report on R1 RCM (RCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.